13.03.2013 - British Shire plc has broadened its therapeutic scope to neonatology by the strategic acquisition of Swedish Premacure AB of Uppsala.
The privately held biotech company is running a dose finding, safety and efficacy Phase II programme for the most common cause of visual loss in childhood – the prevention of retinopathy of prematurity (ROP). Currently, only symptomatic treatment is available for ROP. Shire will purchase Premacure for an undisclosed upfront fee and success-dependent milestones.
In ROP, preterm infants (born before 31 weeks of gestation) lack specific growth factors, such as insulin-like growth factor 1 (IGF-1), which supports normal childhood development and which is involved in ROP. The Swedish have developed a first-in-class recombinant protein replacement therapy termed rhIGF-I/rhIGFBP-3 (insulin-like growth factor-1 binding protein-3) for the orphan disease. The company believes administration of IGF-1 to premature infants, as a substitute for the maternal and endogenous source, allows for the establishment of a physiological level of the hormone comparable to that present in utero.
Shire said it will continue the ongoing Phase II study, the primary goal of which is to restore the IGF-1 levels in preterm infants to those found during normal in utero development. „ We will build on the work that Premacure has done and will apply Shire’s proven ability in developing protein replacement therapies for rare disorders to bring this much needed therapy to the market,” said Flemming Ornskov, CEO Designate of Shire. The treatment targets a patient population of 1,100–1,500 in the US alone .
12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.
26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.
20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).
30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.
SuperScript® III Reverse Transcriptase (RT) is a proprietary mutant of SuperScript® II RT that is active at 50°C and has a half-life of 220 minutes, providing increased specificity with gene-specific primers (GSPs) and the highest cDNA yield of all RTs. more